Summary: Researchers have successfully kept a 3D-printed human liver alive for 30 days
3D
bioprinted thick hepatic constructs with vascular network as
a physiologically relevantin
vitroorgan model
Author
links open overlay panel,,,,,,,
Abstract
Establishing
adequate vascularization to engineered organs remains a
significant challenge that must be addressed. This study
presents a novel approach to fabricating viable thick
metabolic tissue (>1 cm3)
for applications in human physiology, fundamental biology,
and medicine. We designed a tissue construct with a
gyroid-shaped architecture to enable uniform flow and
surface shear stress that adequately covers the inner
surfaces of cell-laden constructs. The constructs
(1 × 1 × 1 cm3)
were fabricated using a digital light projection (DLP)
printer with a cell-laden poly(ethylene glycol)
(PEG)/gelatin methacryloyl (GelMA) bioink combined with
human hepatocytes (HepG2), followed by coating the
interconnected vascular channels with human endothelial
cells (ECs). These constructs were then placed in flow
chambers connected to a medium reservoir for continuous
perfusion for up to 30 days. The constructs retained their
original dimensions, and the cells maintained a greater than
85 % viability at all time points. Immunofluorescent
staining confirmed hepatocytes and ECs using cell-specific
markers (HNF4-α/albumin for hepatocytes and vWF for ECs).
The EC layer effectively lined the vascular lumens, while
viable hepatocyte aggregates populated the interior of the
constructs. Functional assays demonstrated that the
hepatocytes produced albumin and bilirubin at levels
comparable to those observed in humans, validating the
metabolic functionality of the hepatic tissue constructs.
This study successfully developed thick, vascularized human
hepatic tissue in anin
vitroenvironment, maintaining
functionality comparable to native liver cells over 30 days.
The innovative gyroid design applied in these organ
constructs represents a significant advancement in
developing physiologically relevantin
vitrovascularized organ models.
1.Introduction
Over
the past several decades, tissue engineering and
regenerative medicine have made remarkable progress,
driven by the integration of diverse scientific
disciplines [1,2].
Despite these advancements, replicating the intricate
architecture and functionality of solid organs remains
a significant challenge [3,4].
This difficulty arises from the need to recreate
micron-scale functional units with complex vasculature
[5,6].
Among these organs, the liver poses unique challenges
due to its multifaceted roles in metabolism and
detoxification, coupled with its highly complex 3D
structure and diverse cellular composition. Numerous
engineering strategies have been explored to fabricate
functional liver tissue constructs [7];
however, none have achieved significant success in
producing thick (larger than 1 cm3),
physiologically relevant liver constructsin vitrodue
to limited vasculature.
In
recent years, 3D printing has emerged as a
transformative tool to develop advanced technologies
for translational applications [1,[8],[9],[10],[11],[12],[13],[14]].
Recognized for its unmatched precision in positioning
cells and biomaterials, 3D bioprinting has
revolutionized the fabrication of physiologically
relevantin vitrotissue
models [15,16].
Using 3D bioprinting, strategies for creating
vascularized tissue constructs have been designed to
address the existing challenges of engineered tissues
and organs [4].
In particular, 3D printing techniques have been
employed to fabricate engineered tissue constructs
with intricate microchannel architectures [17].
For instance, sacrificial materials have been
extensively investigated for fabricating desired
geometric features by encasing a non-sacrificial
component within a sacrificial material and removing
it [18].
This approach can create a complex network resemblingin vivovasculature
in vascular networks [19].
Seeding primary endothelial and perivascular cells
into the microchannel structure formed perfusable
vascular tubes with endothelial barrier function,
similar to native vessels. Despite the enormous
potential of 3D printing in achieving vascularization
within engineered tissues and organs, several
challenges persist. While branched networks [20]
or multichannel structures enable constructs to be
perfused, regions with insufficient nutrient and
oxygen supply remain devoid of blood flow. Overcoming
these limitations is crucial for achieving the
viability, functionality, and clinical relevance of
vascularized tissue constructs.
The
gyroid design, initially discovered by mathematician
Alan Schoen in 1970 during his NASA research, is
renowned for its smooth, continuous, and
non-intersecting surfaces [21,22].
This unique geometry makes it an optimal choice for
applications requiring efficient material utilization
and functionality. The gyroid's structural integrity
consists of an interconnected and continuous network
of microchannels, facilitating uniform fluid flow
throughout the material. We hypothesized that gyroid
design-incorporated tissue constructs would maintain
cell viability and function through constant
perfusion. This construct would provide an optimal
environment to support cell viability and sustain
cellular functions when cells are integrated into its
intricate network of interconnected channels.
In this
study, we aimed to develop a fully perfusable
hepatic tissue construct (1 × 1 × 1 cm3)
with a gyroid structure (Fig.
1). The primary objective
was to evaluate the construct's viability for more
than 30 daysin vitrowhile
maintaining its hepatic functions, including albumin
and bilirubin secretion. To achieve this, we first
optimized a bioink for the digital light processing
(DLP) printing process and fabricated hepatic tissue
constructs using the optimized bioink system.
Subsequently, the printed hepatic tissue constructs
were integrated with a perfusion system and assessed
for tissue survival, phenotypic expression, and
hepatic functions.
Fig. 1.Schematic
illustration of the fabrication process for
perfusable, large-scale hepatic tissue
constructs (1 × 1 × 1 cm3)
containing hepatocytes and endothelial cells
(ECs) using a digital light processing (DLP)
bioprinting technique. The bioprinted hepatic
construct is integrated with a perfusion
bioreactor system, providing physiologically
relevant conditions.
2.Methods
and methods
2.1.Materials
Poly(ethylene
glycol)-diacrylate (PEG-DA) with molecular weights
of 1 kDa and 4 kDa, 4-arm-PEG acrylate (PEG-A) with
molecular weights of 10 kDa and 20 kDa, and
8-arm-PEG-A with molecular weights of 10 kDa and
40 kDa were procured from Creative PEGWorks (Durham,
NC). Lithium phenyl(2,4,6-trimethyl
benzoyl)phosphinate (LAP) was obtained from Tokyo
Chemical Industry (Tokyo, Japan), and
2,2′-Dihydroxy-4,4′-dimethoxybenzophenone-5,5′-bis(sodium
sulfonate) (Maxguard R1800) was purchased from Lycus
LTD (El Dorado, AR). Gelatin methacryloyl (GelMA)
was synthesized by dissolving type A gelatin (∼300 g
bloom) in CB buffer (0.25 M buffer comprising
7.95 mg/mL sodium carbonate and 0.73 mg/mL sodium
bicarbonate in 1 L distilled water), as described in
our previous work. Methacrylic anhydride (MAA) was
then added to the gelatin solution, and the reaction
was allowed to proceed for 3 h. The degree of
methacrylate (%) of the GelMA was measured by1H
NMR spectroscopy. All chemicals were purchased from
Millipore Sigma (St. Louis, MO), unless otherwise
indicated.
2.2.Cell
culture
Human
hepatocellular carcinoma cell line (HepG2) was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and expanded in 225 cm2cell
culture flasks until 80 % confluence was achieved
with Dulbecco's Modified Eagle's Medium (DMEM, high
glucose). The medium was supplemented with 10 %
fetal bovine serum (FBS) and 1 %
antibiotic/antimycotic. The cells were incubated in
5 % CO2at
37°C and were changed with fresh media every 3 days.
Human umbilical vein endothelial cells (HUVECs) were
cultured in EGM-2 (Lonza, Morrisville, NC) complete
medium containing 2 % (v/v) fetal bovine serum
(FBS), multiple recombinant human growth factors
including vascular endothelial growth factor (VEGF),
fibroblast growth factor (FGF), insulin growth
factor-1 (IGF-1), and epidermal growth factor, as
well as hydrocortisone, heparin, and ascorbic acid.
The culture medium was changed every 3 days, and the
cells were incubated in 5 % CO2at
37°C. All cell culture-related agents were purchased
from HyClone (Logan, UT) unless otherwise indicated.
2.3.Construct
design and fabrication
ABAQUS/Standard®
6.13 finite element (FEM) software (Simulia,
Dassault Systems, Waltham, MA) was employed to
simulate the flow dynamics within the designed
hepatic tissue constructs. In the preprocessing
stage, the 3D CAD models of the gyroid and lattice
structures were imported into the software as
continuous entities for analysis.
The 3D CAD
models of the gyroid and lattice structures were
designed using SolidWorks® and exported as a
stereolithography (STL) file. Both gyroid and
lattice structures, each measuring 1 × 1 × 1 cm3,
were enclosed within solid outer layers, with
openings retained on the inlet and outlet sides to
facilitate integration with the perfusion
bioreactor system. The cell-laden hydrogel
constructs had a volume of 209.59 mm3for
the gyroid structure and 213.98 mm3for
the lattice structure. A detailed comparison of
these constructs is provided inTable
1. The STL file was sliced
along the Z-axis, and each layer was projected
using a DLP system to fabricate the designed 3D
structure. To ensure sterility, components of the
DLP printer susceptible to contamination, such as
the stage and vat, were thoroughly sterilized
prior to printing.
Table
1.Comparison of
gyroid and lattice constructs (1 × 1 × 1 cm3dimension):
porosity, wall thickness, surface area, and
channel size.
Empty
Cell
Gyroid
Lattice
Volume
(mm3)
209.59
213.98
Porosity
(%)
76.3
75.7
Wall
thickness (μm)
300
730
Surface
area (mm2)
1490
1170
Channel
size (mm)
1.7
1.3
DLP
bioinks were formulated by combining GelMA with
PEGs. The concentration of GelMA was maintained at
2 wt% across all bioink formulations, while various
types of PEG polymers were incorporated at a
concentration of 5 wt%. The formulations were
dissolved in phenol-free DMEM supplemented with
0.2 wt% LAP and 0.05 wt% Maxguard R1800 (UV
absorber). The solution was stirred for 1 h at 40 °C
and filtered through a 0.45-μm syringe filter. HepG2
cells were resuspended in the bioink at 10 × 106 cells/mL.
A
total of 11 mL of cell-laden bioink was loaded into
the vat for fabrication. DLP printer (Miicraft,
Jena, Germany) was conducted by sequentially
projecting images of each layer onto the bioink and
raising the Z-stage incrementally. The printing
parameters were set to a 50-μm layer thickness and
40 s of curing time per layer. Six cell-laden gyroid
constructs (1 × 1 × 1 cm3)
were printed simultaneously, each consisting of 200
layers. The total fabrication time was 187 min.
Following fabrication, the constructs were briefly
rinsed with media to remove residual bioink and then
immersed in fresh media for further processing.
2.4.Optimization
of PEG/GelMA bioink formulation for the DLP process
To
optimize the PEG/GelMA bioink formulation for the
DLP printing process, various PEG polymers with
different arm numbers and molecular weights were
combined with 2 wt% GelMA. These formulations were
systematically evaluated for compressive mechanical
properties, printing accuracy, and dimensional
stability.
The
compressive mechanical properties of the PEG/GelMA
constructs were evaluated using an Instron Universal
Testing System (Model #5544, Instron Corporation,
Issaquah, WA) equipped with a 100 N load cell.
Testing was performed at a crosshead speed of
1 mm/min until 25 % compressive strain was achieved.
The compressive modulus (Young's modulus) was
determined using Equation(1),
where E is Young's modulus, σ is stress, andεis
a strain.(1)E=σ(ε)ε
Printing
accuracy was evaluated by determining the percentage
deviation between the intended design dimensions and
the actual dimensions of the printed PEG/GelMA
constructs. To assess dimensional stability in
aqueous conditions, the printed PEG/GelMA constructs
were immersed in PBS, and changes in their
dimensions (swelling ratio) were monitored after
24 h.
2.5.Cell
viability and ATP activity
The
cell viability of the cell-laden PEG/GelMA
constructs was assessed using a Live/Dead® staining
assay kit. Live/Dead® analysis was performed
employing a calcein-ethidium stain. The calcein-Am
(green) component indicates intracellular esterase
activity, characteristic of living cells, while the
ethidium homodimer-1 (red) component signifies a
disruption of plasma membrane integrity. A solution
comprising 0.5 μl/mL calcein (4 mM) and 1 μL/mL
ethidium (2 mM) in PBS was prepared. Subsequently,
the constructs were incubated in this solution for
30 min, shielded from light, and imaged using a
Leica Macro-Confocal microscope (Nussloch, Germany).
These images were exported as TIF files, which were
subsequently analyzed to quantify the percentage of
cellular viability.
The
ATP activity in the cell-laden PEG/GelMA constructs
was assessed using the CellTiter-Glo® Luminescent
Assay (Promega, Madision, WI). The constructs were
rinsed with sterile PBS, and an ATP assay reagent
was added to ensure complete lysis and ATP release.
After a 10-min incubation at room temperature, the
luminescence was measured using a plate reader. ATP
content was quantified by comparing luminescence
values to a standard curve prepared with known ATP
concentrations, measuring cellular metabolic
activity.
2.6.Perfusion
set-up
The
perfusion system comprised a flow chamber, bubble
trap, medium reservoir, tubing, and micro-pump. Flow
chambers for this trial were constructed using a
silicone spacer with a 1 cm square recess in the
center and attachment points for tubing on both
sides of the recess. The constructs were aligned to
ensure that the two open faces were parallel to the
inlet/outlet, and the closed walls were aligned with
the solid silicone walls of the recess. Acrylic
sheets were employed to seal the system by placing a
solid piece on the open face of the silicone mold
and securing it with six bolts to create a
watertight seal. Tubing was connected at the
inlet/outlet to facilitate media flow. Perfusion was
established by pumping media from the reservoir
through the bubble trap, through the sample, and
back to the reservoir via a peristaltic pump
(Elemental Scientific Inc., Omaha, NE). The flow
rate was set to 100 μL/min, and the total medium
volume contained in the perfusion system was 6 mL.
2.7.Immunofluorescent
analysis
The
constructs were fixed in 10 % neutral buffered
formalin (NBF) overnight at 4 °C. Subsequently, they
were permeabilized with 0.2 % (v/v) Triton X-100 for
2 h. The sectioned samples were stained with
antibodies against hepatocyte nuclear factor 4-α
(HNF4A, 1:200, Abcam), albumin (1:200,
Thermofisher), bilirubin (1:200, Biomatik), and von
Willebrand factor (vWF, 1:400, Aligent). Nuclei were
counterstained with DAPI, and the resulting images
were acquired using fluorescence microscopy (BX63
microscope; Olympus, Tokyo, Japan).
2.8.Hepatic
function measurement
Albumin
was measured using Human Albumin SimpleStep ELISA
Kits (ab227933, Abcam, Cambridge, UK). Media was
reserved from each media change and frozen until the
assay was performed. Then, 50 μL of the sample was
assayed according to the kit protocol and compared
to a standard curve to calculate the albumin
concentration in the sample. All samples were
measured using a plate reader (SpectraMax M5,
Molecular Devices, San Jose, CA).
Bilirubin
concentrations were assayed using a colorimetric
assay kit for total and direct bilirubin (ab235627,
Abcam). 50 μL of media, reserved from media changes,
was reacted with a reagent mix and measured for
endpoint absorbance using the plate reader. A
standard curve was used to calculate the amount of
bilirubin per assay well (μg/well), which was then
converted to μg/mL.
2.9.Vascularized
hepatic tissue construct
To
fabricate vascularized hepatic tissue constructs,
HUVECs were seeded onto the printed hepatic
constructs at a density of 2 × 106 cells.
Subsequently, the constructs were incubated in a 5 %
CO2atmosphere
at 37 °C for 3 h. Following this initial incubation,
the constructs were flipped, an additional 2 × 106 cells
were seeded on the opposite side, and the construct
were incubated for another 3 h. Following seeding,
the constructs were integrated into a perfusion
system, which was maintained throughout the study. A
1:1 mixture of HepG2 medium (DMEM high glucose
supplemented with 10 % FBS and 1 %
antibiotic-antimycotic) and EGM-2 complete medium
was used. A total of 6 mL of co-culture medium was
replaced every 3 days during perfusion. The
vascularized hepatic tissue constructs were
evaluated by assessing cell viability, cellular
morphology, phenotypic expression, and hepatic
functions, as described above.
2.10.Statistical
analysis
Statistical
analysis and quantification of data collected from
Live/Dead® staining assay, ATP assay, and functional
assays were performed using GraphPad Prism software.
All data are presented as mean ± standard deviation
from our experimental samples. Statistical
significance was assessed using a two-way ANOVA with
multiple comparisons.P < 0.05
was considered statistically significant.
3.Results
3.1.Optimized
bioink formulation for the DLP process
To optimize
the bioink formulation for DLP-based fabrication
of hepatic tissue constructs, a series of PEG
polymers with varying numbers of arms and
molecular weights were combined with GelMA. Among
these formulations, the 10 kDa 4-arm PEG-A
demonstrated the highest compression modulus
compared to the other formulations (Fig.
2A and B). Printing
accuracy was assessed by comparing the designed
printing resolution with the actual printed
resolution. The 10 kDa 4-arm PEG-A exhibited
superior printing accuracy (Fig.
2C). Dimensional stability
was evaluated through swelling ratio measurements.
The results showed that the 10 kDa and 20 kDa
4-arm PEG-As, along with the 10 kDa and 40 kDa
8-arm PEG-As, had swelling ratios below 10 %,
indicating minimal dimensional changes in aqueous
environments (Fig.
2D).
Fig. 2.Optimization
of PEG/GelMA composite bioink formulationswith
various PEG types (diacrylate, 4-arm, and
8-arm) and molecular weights. (A)
Compressive stress-strain curves and (B)
compressive modulus values demonstrate
mechanical properties of the bioinks
(n = 5). (C) Printing accuracy (%) comparing
printed resolution to the designed
resolution (n = 5). (D) Swelling ratio (%)
showing dimensional changes after 24 h in
aqueous conditions (n = 5). (E) Live/dead
staining images of printed constructs
containing HepG2 cells for various PEG/GelMA
formulations. (F) ATP activity analysis to
assess the metabolic activity (n = 5). ∗P < 0.05
compared with other groups at Day 1, ∗∗P < 0.05
compared with other groups at Day 3, and ∗∗∗P < 0.05
compared with other groups at Day 7. (G) The
4-arm PEG (10k)/GelMA composite bioink
achieves the best printing outcomes,
demonstrated by diverse construct shapes,
including 2-channel, meshed, multi-channel,
and ear-shaped designs. All data are
represented as mean ± SD.
To
evaluate the biological properties of the
PEG/GelMA-based bioink formulations, HepG2 cells
were DLP-printed using various
PEG/GelMAformulations. Live/Dead® staining confirmed
that none of the formulations compromised cell
viability within the printed constructs (Fig.
2E). Moreover, cells
demonstrated self-assembly behavior, forming
aggregates in the 4 kDa PEG-DA and 10 kDa 4-arm
PEG-A formulations. ATP assays further indicated
cellular proliferation over time in the printed
constructs, except for those fabricated with 1 kDa
PEG-DA and 10 kDa 8-arm PEG-A (Fig.
2F).
Based
on the results, the 10 kDa 4-arm PEG-A and GelMA
formulation was selected as the DLP bioink for
subsequent experiments. This formulation
demonstrated the capability to fabricate diverse
construct shapes with high resolution using the DLP
process (Fig.
2G).
3.2.FEM
simulation and construct fabrication
Based on FEM
simulation results, the gyroid-shaped architecture
effectively distributed uniform flow and surface
shear stress across the entire inner surfaces of
cell-laden tissue constructs. This design strategy
ensures a consistent supply of oxygen and
nutrients to cells within the construct during
perfusion. The targeted construct had dimensions
of 1 × 1 × 1 cm3,
with 76.3 % of the porosity of the gyroid
constructs (Table
1). The simulation results
were validated, confirming the absence of vortex
formation and the consistent application of shear
stress to all channels at a flow rate of
100 μL/min (Fig.
3A). Particularly, the
gyroid structure showed uniform surface shear
stress up to 300 μL/min flow rate (Supplementary
Fig. 1). In contrast to
the gyroid structure, the lattice structure
(75.7 % porosity) exhibited challenges in
achieving uniform flow and surface shear stress
distribution. The lattice structure revealed a
high surface shear stress distribution.
Fig. 3.Design
strategy and fabrication of perfusable
hepatic tissue constructs.3D
CAD design and FEM simulation comparing (A)
gyroid-shaped and (B) lattice constructs,
highlighting uniform fluid flow (flow rate
and surface shear stress) in the
gyroid-shaped design at a flow rate of
100 μL/min. (C) Schematic illustration of
the DLP bioprinting process. (D) CAD model
and cross-sectional view of the
gyroid-shaped construct, showing a uniform
wall thickness of 300 μm. The cell-laden
constructs were fabricated using the DLP
bioprinting technique.
Using
the DLP process, the PEG/GelMA composite bioink was
utilized to fabricate cell-laden gyroid constructs.
The gyroid constructs (1 × 1 × 1 cm3)
containing 10 × 106 cells/mL
of HepG2 cells were successfully fabricated.
3.3.Gyroid
vs. lattice structures
To validate
the gyroid structure under perfusion conditions,
cell-laden constructs with gyroid and lattice
structures were cultured under static and
perfusion conditions. Live/Dead® staining of the
constructs was performed on days 0, 10, and 20.
The samples were observed in three distinct
construct regions: inlet, middle, and outlet (Fig.
4A). Immediately after
printing, most cells exhibited uniformly
distributed viable cells (green), with only a few
dead cells (red). After 10 days in culture, the
samples showed more aggregated cells than the day
0 samples, indicating active cellular
proliferation under static and perfusion
conditions (no significant difference at 10 days
in culture) (Fig.
4B and C). Live/Dead
staining revealed >90 % cell viability at days
0 and 10. However, the gyroid constructs under
perfusion exhibited higher cell viability compared
to both lattice and gyroid constructs under static
conditions at day 20 in culture (Fig.
4B and C). Although the
gyroid construct under perfusion exhibited
slightly higher cell viability than the lattice
construct under perfusion, there was no
statistically significant difference.
Fig. 4.Cell
viability analysis of the printed hepatic
constructs.(A) The
hepatic constructs were segmented into three
regions: inlet, middle, and outlet for
analysis. (B) Live/dead staining images of
lattice and gyroid constructs under static
and perfusion conditions at 0, 10 and 20
days. (C) Quantified cell viability (%)
based on live and dead cells within the
printed constructs (n = 5). ∗∗P < 0.05,
∗∗∗P < 0.01.
All data are represented as mean ± SD. TheP-values
by a two-way ANOVA with multiple comparisons
are indicated.
Cellular
function was confirmed by immunofluorescent
staining of albumin and bilirubin. Notably, HepG2
cells in the gyroid construct under perfusion
conditions exhibited enhanced cellular
organization (Fig.
5A). Furthermore, distinct
aggregates were observed at day 10, which
progressively expanded and matured throughout day
20. These findings revealed a substantial
disparity between the gyroid perfusion group and
both static and perfusion lattice groups,
indicating a higher level of hepatic function
within the perfusion group.
Fig. 5.Hepatic
cell phenotype and function.(A)
Immunofluorescent staining of printed
hepatic constructs for albumin and bilirubin
at days 0, 10, and 20. Albumin (red),
bilirubin (green), and DAPI (blue). (B)
Quantification of albumin production
(n = 6). (C) Quantification of urea
production (n = 6). (D) Quantification of
bilirubin production (n = 6). ∗∗P < 0.05.
All data are represented as mean ± SD. TheP-values
by a two-way ANOVA with multiple comparisons
are indicated. (For interpretation of the
references to color in this figure legend,
the reader is referred to the Web version of
this article.)
The
hepatic tissue constructs demonstrated the capacity
to produce physiologically relevant levels of
albumin, urea and bilirubin throughout the 20-day
duration (Fig.
5B–D). At day 20, the gyroid
constructs under perfusion conditions exhibited
significantly elevated levels of albumin and
bilirubin compared to lattice and gyroid groups
under static conditions. Despite the gyroid
constructs exhibiting slightly higher values than
the lattice constructs under perfusion conditions,
no statistically significant difference was
observed. While both perfusion groups demonstrated
increased hepatocyte aggregation and functional
expression, the unique gyroid design demonstrated
the ability to produce elevated levels of albumin
and bilirubin to a statistically significant extent.
These findings establish a correlation between the
increased aggregation observed in the perfusion
groups and the enhanced functionality of the hepatic
tissue constructs.
3.4.Vascularized
hepatic tissue construct
To develop
the vascularized hepatic tissue construct, HUVECs
were successfully seeded into the hepatic gyroid
constructs. These constructs were subsequently
integrated with the perfusion system (Fig.
6A). Continuous perfusion
was maintained throughout the constructs without
evidence of uncontrolled leakage for the entire
trial duration (Supplementary
Figure 2), and the
original dimension of the constructs was also
maintained during the 30-day perfusion period (Supplementary
Figure 3).
Fig. 6.Vascularized
hepatic tissue constructs.(A)
Schematic illustration and photograph of the
perfusion system for DLP-printed gyroid
hepatic constructs containing HepG2 cells
and ECs. The liver constructs were
positioned in a PDMS flow chamber for
perfusion. (B) Live/Dead staining images of
the hepatic constructs over the 30-day
perfusion period. (C) Quantification of cell
viability (%) in different regions of the
constructs during the 30-day perfusion
(n = 3). (D) Cell size distribution in
various regions of the constructs throughout
the 30-day perfusion (n = 3). All data are
represented as mean ± SD. The p-values by a
two-way ANOVA with multiple comparisons are
indicated.
Live/Dead®
staining of the vascularized hepatic tissue
constructs under perfusion on days 10, 20, and 30)
was performed. The samples were examined in three
distinct construct regions: inlet, middle, and
outlet (Supplementary
Figs. 4, 5, and 6). The
majority of cells exhibited uniformly distributed
viable cells (green), with only a few dead cells
(red) (Fig.
6B). After 10 days of
culture, the samples exhibited a higher density of
aggregated cells compared to the day 0 samples,
indicating an active cellular proliferation under
perfusion. The 3D-rendered images of various planes
revealed aggregated cells, which are highly probable
to be hepatocytes. Quantitatively, >85 % cell
viability was presented at all time points under
perfusion; on days 0, 10, 20, and 30 (Fig.
6C). Cell viability is
maintained by nutrient delivery through the
perfusion of tissue constructs without any external
support during the 30-day trial. During perfusion,
HepG2 cells settled and self-aggregated to form cell
clusters. These gradually formed well-defined cell
aggregates over 30 days. The cell size distribution
showed a wide range of sizes, likely due to the
increased aggregation of hepatocytes over time (Fig.
6D).
Cell
proliferation was confirmed by Ki67
immunofluorescent staining. Proliferation was
prominent (Ki67-expressed, green) in the aggregated
cells (hepatocytes) (Supplementary
Figure 7A). Furthermore, the
cell proliferation in the tissue constructs was
determined by the luminescent ATP Detection Assay
Kit. The ATP assay confirmed that the cells within
the samples are metabolically active (Supplementary
Figure 7B). The results
showed that the ATP level of the day 20 samples was
significantly higher than that of the day 10
samples, and the day 30 sample was slightly lower
compared with the day 20 samples (Supplementary
Fig. 7C). These findings may
be attributed to the high cell confluence within the
limited space in the construct.
To confirm
the hepatic phenotypes, the constructs were
co-stained with HNF4A and albumin. HNF4A-positive
cells within the constructs indicate aggregated
hepatocytes. Hepatocytes were further confirmed by
HNF4A and albumin (Fig.
7A). Single hepatocytes
(green) at day 0 transformed into aggregated
morphology at day 10, accompanied by albumin
expression (red). The day 20 and day 30 samples
consistently exhibited expression of the
hepatocyte-specific antibodies (HNF4A, green) and
albumin (red). Endothelial cells were confirmed by
endothelial cell-specific antibodies (vWF). The
endothelial cells (red) are uniformly distributed
throughout the construct. The day 20 and day 30
samples clearly demonstrate an endothelial layer
covering the lumen of the construct, with viable
hepatocyte aggregates present within the
construct's interior region. This observation was
confirmed by double staining with vWF (red;
endothelial cells) and DAPI (blue; hepatocytes) (Fig.
7B). This finding suggests
that the viability of hepatocytes is maintained by
perfusate diffusion, which provides essential
nutrients and oxygen. This demonstrates the
functional capacity of the endothelial cells
within the vascularized construct. (L: lumen of
the vascular channel).
Fig. 7.Cell
phenotype and hepatic functions.(A)
Immunofluorescent staining for HNF4A (green)
and albumin (red) in vascularized hepatic
tissue constructs at days 0, 10, 20, and 30
post-perfusion. (B) Immunofluorescent
staining for vWF (red) and DAPI (blue) in
vascular tissue constructs at days 0, 10,
20, and 30 post-perfusion. L: Lumen. (C)
Total albumin production per day per
scaffold during the 30-day perfusion: days
3, 6, 9 (n = 15); days 12, 15, 18, 21
(n = 10); days 24, 27, 30 (n = 5). (D)
Quantification of bilirubin production from
the printed hepatic constructs during the
30-day perfusion: days 3, 6, 9 (n = 15);
days 12, 15, 18, 21 (n = 10); days 24, 27,
30 (n = 5). All data are represented as
mean ± SD. (For interpretation of the
references to color in this figure legend,
the reader is referred to the Web version of
this article.)
Quantitative
analysis of albumin and bilirubin production was
performed using media collected throughout the
30-day perfusion period. The perfusate from samples
collected at various time points consistently
demonstrated albumin production. Notably, the
accumulated total albumin produced over 21 days of
perfusion reached approximately 110 μg, a level
comparable to that found in human blood (Fig.
7C). Similarly, the total
bilirubin in the collected media revealed continuous
production by the bioprinted tissue constructs
during the 30-day perfusion period (Fig.
7D). The bilirubin
concentration ranged from 1 to 6 μg/mL across the
time points, aligning with levels observed in human
blood, indicating sustained functionality of the
hepatocytes within the constructs.
4.Discussion
To
fabricate vascularized liver tissue, a study developed
a 3D liver model incorporating branched vascular
networks to enhance perfusion [20].
However, limitations in nutrient and oxygen diffusion
persist in regions of the construct due to the
inherent properties of hydrogel-based materials.
Another investigation utilized 3D bioprinted microgels
to create implantable vascularized tissues [23],
which similarly experienced inadequate nutrient and
oxygen delivery, resulting in non-perfused areas.
Volumetric bioprinting of organoids using optically
tunable hydrogels has demonstrated potential in
generating liver-like metabolic biofactories [24].
This study explored the flow characteristics of three
triply periodic minimal surface (TPMS) geometries. The
evaluation involved measuring albumin and GLDH levels
after 24 h of perfusion. Although these findings
suggest the constructs could serve asin vitroliver
models, the study did not assess their long-term
functionality or physiological relevance to human
liver tissue. In our study, we assessed hepatocyte
function and maturity over a 30-day period by
quantifying key hepatic markers, including albumin and
bilirubin production.
This
study presents a novel approach to fabricating
vascularized large tissue constructs that maintain
cellular viability and metabolic function for a
prolonged period. Motivated by the NASA Vascular
Tissue Challenge [25],
which is part of the Centennial Challenges program,
this study addresses the continued challenge
associated with vascularization of tissue-engineered
organ constructs. The challenge required the
development of a vascularized human organ construct
(1 cm3)
integrated with active perfusion for a 30-day trial.
In this challenge, we took an approach of bioprinting
vascularized liver tissue constructs by incorporating
human hepatocytes and ECs. The constructs were
evaluated on their ability to maintain over 85 % cell
viability and demonstrate key hepatic functions,
including albumin and bilirubin production. We
utilized the gyroid design to provide evenly
distributed active perfusion to the hepatic tissue
construct. This design ensures uniform flow and low
shear stress across the inner surfaces of the
cell-laden tissue constructs, facilitating a
consistent supply of oxygen and nutrients to the cells
within the construct.Supplementary
Videoprovides a comprehensive
overview of the entire process, encompassing bioink
preparation, DLP bioprinting, and perfusion procedure.
In
this study, we utilized a composite bioink system
comprising PEG and GelMA. PEG was hypothesized to
contribute suitable mechanical properties and printing
precision, while GelMA was expected to enhance
biological compatibility, supporting tissue-specific
cell types [26].
To optimize the bioink formulation for the DLP
printing process, various PEG polymers were combined
with GelMA. The PEG/GelMA composite bioinks
demonstrated distinct mechanical properties, printing
accuracy, and dimensional stability depending on the
number of arms and molecular weights of the PEG
polymers. Compression testing confirmed the mechanical
properties of each formulation and its suitability for
the printing process. In hydrogel-based constructs,
enhanced mechanical strength is particularly
advantageous for DLP-based bioprinting, which depends
on a layer-by-layer fabrication strategy. For
successful 3D construct formation, each printed layer
must retain sufficient structural integrity to support
the subsequent layers during printing. High printing
accuracy is also critical for fabricating complex
geometries, such as gyroid structures. Furthermore,
dimensional stability - specifically, resistance to
swelling or deformation - is essential for maintaining
construct integrity during long-term perfusion
culture. Based on these criteria, the optimized bioink
formulation consisting of 5 wt% 10 kDa PEG-A and 2 wt%
GelMA, exhibited outstanding mechanical properties,
printing precision, dimensional stability, and
biological compatibility.
This
study emphasized the critical role of efficient fluid
dynamics in engineered tissue constructs and
demonstrated the effectiveness of gyroid-shaped
architectures in overcoming challenges associated with
functional vasculature fabrication. The gyroid
structure, characterized by its interconnected
channels [27],
promotes uniform fluid flow and optimal surface shear
stress, enhancing nutrient and oxygen distribution
throughout the cell-laden construct. In our construct
design, the channel size (1.7 mm) in the gyroid-shaped
architecture was determined based on the wall
thickness, which was set at 300 μm. This value was
chosen to exceed the typical diffusion limit of
hydrogel-based constructs (∼200 μm) [28],
ensuring sufficient nutrient and oxygen transport to
the encapsulated cells. To compare two different
construct designs, we ensured that the gyroid and
lattice structures had closely matched volume (mm3)
and porosity (%) in our experiments. Our results
demonstrate that gyroid-shaped constructs achieved a
more uniform cell distribution under perfusion
conditions compared to lattice constructs. These
findings align with FEM simulations, which predicted
higher surface shear stress and irregular flow rates
in lattice structures.
Both
gyroid and lattice constructs showed improved cellular
distribution under perfusion compared to static
conditions. However, gyroid constructs outperformed
lattice constructs by achieving more uniform cell
distribution and higher cell viability after 20 days
in culture. While lattice constructs under perfusion
conditions also enhanced cellular distribution, the
elevated shear stress in these constructs led to lower
albumin and bilirubin production compared to gyroid
constructs. This highlights the importance of
balancing fluid flow optimization with shear stress
minimization, demonstrating the critical need for
construct designs tailored to specific applications.
Gyroid-shaped constructs provide a promising solution
for enhancing cell viability and functionalityin vitroby
effectively mimicking the oxygen and nutrient delivery
systems found in living tissues.
A
key observation in the vascularized hepatic tissue
constructs containing hepatocytes and ECs was the
homogeneous cellular distribution and well-defined
hepatocyte aggregates within the gyroid constructs
under perfusion conditions. The hepatic constructs
consistently maintained phenotypic expression of both
hepatocytes and ECs. Notably, EC coverage along the
luminal surfaces of the constructs remained intact
throughout the 30-day trial. Furthermore, the
vascularized hepatic constructs produced
physiologically relevant levels of albumin and
bilirubin (in the microgram range) over the entire
trial period. This achievement can be attributed to
the large-scale construct (1 cm3)
with uniform cell distribution, maturation, and high
cell viability.
While
this study offers valuable insights into the potential
of 3D printing for hepatic tissue constructs, several
limitations warrant consideration for future studies.
First, HepG2 cells, a cancerous liver cell line known
for their high proliferative capacity and resilience,
were utilized in this study. Although this approach
facilitated the optimization of design and fabrication
parameters, future studies should investigate
alternative cell types to develop more physiologically
relevant models. Second, the constructs included only
HepG2 cells and HUVECs. To create a more comprehensive
model, future studies should incorporate additional
cell types, such as Kupffer cells, stellate cells, and
sinusoidal ECs [29].
While the use of primary liver cells presents
challenges related to cell expansion, exploring
alternative cell sources, such as stem cells, could
help bridge the gap toward clinically relevant models
[30,31].
Despite these limitations, this study demonstrates a
robust proof of concept for bioprinting hepatic tissue
equivalents. The ability to generate physiologically
relevant tissue models holds significant promise for
advancing drug screening, personalized medicine, and
tissue regeneration therapies.
5.Conclusion
We
successfully engineered thick, vascularized human
hepatic tissue constructs in anin vitroenvironment,
maintaining key metabolic functions comparable to
native liver tissue over a 30-day culture period. This
was achieved through the development of optimized
PEG/GelMA bioink formulations tailored for DLP-based
bioprinting. The introduction of a novel gyroid
architecture enabled the fabrication of perfusable
constructs, supporting uniform cell distribution,
enhanced viability, and sustained hepatic
functionality under dynamic culture conditions.
Moreover, our perfusable hepatic constructs
demonstrated albumin and bilirubin production levels
comparable to those found in human blood. Our findings
highlight the potential of gyroid-structured
constructs to advance the field of organ engineering
by providing a platform for physiologically relevant,
perfusablein vitroliver
models. Future work should focus on integrating
multiple liver-specific cell types, exploring
alternative biomaterials, and assessing long-term
functionality for applications such as hepatotoxicity
testing and drug screening. The innovative application
of the gyroid design in this study represents a
significant step forward in the development of
next-generation vascularized organ models.
CRediT
authorship contribution statement
Young-Wook
Moon:Writing – original
draft, Methodology, Investigation, Formal analysis,
Data curation.Timothy
Dobroski:Writing – original
draft, Methodology, Investigation, Formal analysis.Kelsey
Willson:Methodology,
Investigation.Jin-Oh
Jeong:Writing – original
draft, Investigation.Colin
Bishop:Writing – review &
editing, Methodology.Anthony
Atala:Funding acquisition,
Conceptualization.James
J. Yoo:Writing – review &
editing, Resources, Funding acquisition,
Conceptualization.Sang
Jin Lee:Writing – review
& editing, Supervision, Resources, Methodology,
Funding acquisition, Conceptualization.
Declaration
of competing interest
The
authors declare that they have no known competing
financial interests or personal relationships that could
have appeared to influence the work reported in this
paper.
Acknowledgment
This
study was supported, in part, byNIH/NIBIB(1P41EB023833),
Medical Technology Enterprise Consortium
(#W81XWH-15-9-0001), and the State of North Carolina
(#30962). This project was awarded 1st place in theNASAVascular
Tissue Challenge. The authors would like to thank Dr.
Anahita Soufivand for providing the Finite Element
Method (FEM) simulation.